Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567618 | 1.00 | CCR1 (0.46) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL21300025 | 0.86 | CCR1 (0.46) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL29497498 | 0.84 | TRPV4 (0.58) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL130934 | 0.84 | TRPV4 (0.58) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL146646 | 0.83 | CCR1 (0.52) | CCR1CCR5CCR8HDAC6NOS3 | |
| Ammonia Solution, Strong SCHEMBL28458759 | 0.82 | TRPV4 (0.56) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL24922473 | 0.81 | CCR1 (0.50) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL25894850 | 0.80 | CCR1 (0.44) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL18639231 | 0.77 | TRPV4 (0.68) | TRPV4 | |
| SCHEMBL12918280 | 0.77 | NOS3 (0.48) | CCR1CCR5CCR8HDAC6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841086-B1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-116917289-A | T-type calcium channel antagonists and uses thereof | 小利兰·斯坦福大学董事会 | 2023-10-20 | — | — | CN | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20080280915-A1 | Insecticidal n-substituted (heteroaryl)alkyl sulfilimines | CORTEVA AGRISCIENCE LLC | 2008-11-13 | — | — | US | disclosed |
| US-20080280915-A1 | Insecticidal n-substituted (heteroaryl)alkyl sulfilimines | CORTEVA AGRISCIENCE LLC | 2008-11-13 | — | — | US | disclosed |
| EP-1989184-A2 | INSECTICIDAL N-SUBSTITUTED (6-HALOALKYLPYRIDIN-3-YL)ALKYL SULFOXIMINES | Dow AgroSciences LLC (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008030266-A2 | INSECTICIDAL N-SUBSTITUTED (HETEROARYL)ALKYL SULFILMINES | DOW AGROSCIENCES LLC (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030266-A2 | INSECTICIDAL N-SUBSTITUTED (HETEROARYL)ALKYL SULFILMINES | DOW AGROSCIENCES LLC (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | CORTEVA AGRISCIENCE LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | CORTEVA AGRISCIENCE LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | CORTEVA AGRISCIENCE LLC | 2007-08-30 | — | — | US | disclosed |
| WO-2007095229-A2 | INSECTICIDAL N-SUBSTITUTED (6-HALOALKYLPYRIDIN-3-YL)ALKYL SULFOXIMINES | DOW AGROSCIENCES LLC (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095229-A2 | INSECTICIDAL N-SUBSTITUTED (6-HALOALKYLPYRIDIN-3-YL)ALKYL SULFOXIMINES | DOW AGROSCIENCES LLC (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | CACNA1G, CACNA1H, CACNB2 | CCR1 2841/4885CCR5 3475/4885CCR8 2881/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | CCR1 2304/4885CCR5 3882/4885CCR8 2308/4885 |
| US-20080280915-A1 | Insecticidal n-substituted (heteroaryl)alkyl sulfilimines | AANAT, GNMT, STS | CCR1 4428/4885CCR5 2792/4885CCR8 3744/4885 |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | NPEPPS, PRDX6, HDHD5 | CCR1 3980/4885CCR5 2886/4885CCR8 2597/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | CCR1 1760/4885CCR5 2794/4885CCR8 2053/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CCR1 2225/4885CCR5 3852/4885CCR8 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.